An Early Phase 1 interventional study of ECC4703 and Placebo in Non-alcoholic Steatohepatitis (NASH), sponsored by Eccogene. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Eccogene · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 186th largest by enrollment of the 460 interventional ones that give a count, is one of 38 that started in 2022, is one of 79 in phase 1, and was the 459th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 38 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Eccogene is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Eccogene has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
This study will be conducted in two cohorts of Single Ascending Dose (SAD) with a dose range from 1mg to 400mg and in four cohorts of Multiple Ascending Dose (MAD) with a dose range of 40mg to 160mg to Investigate the Safety, Tolerability, PK, and PD of ECC4703 in Healthy Volunteers and Participants with Treatment Unnecessary LDL-C under 160 mg/dL
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for Part 2 (MAD) Cohorts B2 to B4
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in each SAD cohort will be randomized to receive placebo
Drug: Placebo
Participants in each SAD cohort will be randomized to receive up to 4 escalating doses (1 mg, 4 mg, 12 mg, 32 mg, 80 mg, 160 mg, 320 mg or 400 mg).
Drug: ECC4703
Participants will be randomized to receive a once-daily dose of placebo for 14 days.
Drug: Placebo
Participants will be randomized to receive a once-daily dose of 1 of 3 escalating doses (40 mg, 80 mg, or 160 mg) for 14 days.
Drug: ECC4703
ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.
Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.
Number of participants with adverse events, with abnormal laboratory test results, abnormal ECGs, abnormal vital signs, and abnormal physical examinations
Safety Assessment evaluated through adverse events, laboratory evaluations, vital signs, ECGs, and physical examination.
Time frame: SAD: Up to 8 days and MAD: Up to 21 days
Pharmacokinetic Parameters: AUC0-24
AUC from time 0 to 24 hour dosing interval
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: AUC0-tlast
AUC from time 0 to the time of last quantifiable non-zero concentration
Time frame: SAD: Up to Day 8
Pharmacokinetic Parameters: AUC0-tau
AUC over a dosing interval from time 0 to time of last quantifiable concentration
Time frame: MAD: Up to Day 21.
Pharmacokinetic Parameters: AUC0-infinity
AUC from time 0 extrapolated to infinity
Time frame: SAD: Up to Day 8
Pharmacokinetic Parameters: Cmax
Maximum observed plasma concentration
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: C24
Observed concentration at 24 hours post dose
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: Ctau
Observed concentration at the end of the dosing interval
Time frame: MAD: Up to Day 21.
Pharmacokinetic Parameters: tmax
Time of the maximum observed plasma concentration
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: tlag
Lag time (time delay between dosing and first observed plasma concentration)
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: t1/2
Apparent terminal elimination half-life
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacokinetic Parameters: Clast
Last measurable non-zero concentration
Time frame: SAD: Up to Day 8
Pharmacokinetic Parameters: tlast
Time of last measurable non-zero concentration
Time frame: SAD: Up to Day 8
Pharmacokinetic Parameters: CL/F
Apparent Clearance
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacodynamic assessment: LDL-C
Measurement of Low Density Lipoprotein Cholesterol
Time frame: SAD: Up to Day 8
Pharmacodynamic assessment: HDL-C
Measurement of High Density Lipoprotein Cholesterol
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: TG
Measurement of Triglycerides
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: TC
Measurement of Total Cholesterol
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: LDL
Measurement of Low Density Lipoprotein
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: VLDL
Measurement of Very Low Density Lipoprotein
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: ApoB
Measurement of Apolipoprotein B
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Pharmacodynamic assessment: Lp(a)
Measurement of Lipoprotein (a)
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: Glucose
Measurement of Glucose
Time frame: MAD: Up to Day 21.
Pharmacodynamic assessment: Serum Insulin
Measurement of Serum Insulin
Time frame: MAD: Up to Day 21.
Thyroid function assessment: TT3
Measurement of Total Triiodothyronine
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: FT3
Measurement of Free Triiodothyronine
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: TT4
Measurement of Total Thyroxine
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: FT4
Measurement of Free Thyroxine
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Thyroid function assessment: TSH
Measurement of Thyroid Stimulating Hormone
Time frame: SAD: Up to Day 8 and MAD: Up to Day 21.
Plan to share: No
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Oct 2023, 14 months.
Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.
Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ECC4703
Non-alcoholic Fatty Liver Disease →
Eccogene